FR13C0046I2 - Vesicules de membrane externe bacterienne ameliorees - Google Patents
Vesicules de membrane externe bacterienne amelioreesInfo
- Publication number
- FR13C0046I2 FR13C0046I2 FR13C0046C FR13C0046C FR13C0046I2 FR 13C0046 I2 FR13C0046 I2 FR 13C0046I2 FR 13C0046 C FR13C0046 C FR 13C0046C FR 13C0046 C FR13C0046 C FR 13C0046C FR 13C0046 I2 FR13C0046 I2 FR 13C0046I2
- Authority
- FR
- France
- Prior art keywords
- pellet
- outer membrane
- membrane vesicles
- collecting
- detergent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0220194.5A GB0220194D0 (en) | 2002-08-30 | 2002-08-30 | Improved vesicles |
EP07012893.9A EP1864679B1 (fr) | 2002-08-30 | 2003-09-01 | Vésicules de membrane externe bactérienne améliorées |
EP03791150A EP1534326B1 (fr) | 2002-08-30 | 2003-09-01 | Ameliorations apportees a des vesicules de membrane externe bacteriennes |
Publications (2)
Publication Number | Publication Date |
---|---|
FR13C0046I1 FR13C0046I1 (fr) | 2013-09-06 |
FR13C0046I2 true FR13C0046I2 (fr) | 2014-05-16 |
Family
ID=9943238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR13C0046C Active FR13C0046I2 (fr) | 2002-08-30 | 2013-07-31 | Vesicules de membrane externe bacterienne ameliorees |
Country Status (21)
Country | Link |
---|---|
US (2) | US20060166344A1 (fr) |
EP (5) | EP2258388B1 (fr) |
JP (3) | JP2006503822A (fr) |
CN (2) | CN1688334A (fr) |
AT (1) | ATE366117T1 (fr) |
AU (1) | AU2003263534B2 (fr) |
BR (1) | BRPI0314094A8 (fr) |
CA (1) | CA2497165C (fr) |
CY (3) | CY1107737T1 (fr) |
DE (1) | DE60314756T2 (fr) |
DK (3) | DK1864679T3 (fr) |
ES (4) | ES2289351T3 (fr) |
FR (1) | FR13C0046I2 (fr) |
GB (1) | GB0220194D0 (fr) |
LU (1) | LU92239I2 (fr) |
MX (1) | MXPA05002316A (fr) |
NZ (1) | NZ538673A (fr) |
PT (3) | PT1534326E (fr) |
RU (1) | RU2325184C2 (fr) |
SI (2) | SI1864679T1 (fr) |
WO (1) | WO2004019977A2 (fr) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1047784T4 (en) * | 1998-01-14 | 2015-06-15 | Novartis Vaccines & Diagnostic | NEISSERA meningitidis ANTIGENS |
NZ508771A (en) | 1998-05-29 | 2003-08-29 | Chiron Corp | Neisseria meningitidis vaccine comprising NmC oligosaccharides, NmB outer membrane proteins, and a carrier |
EP2270172B1 (fr) | 1999-05-19 | 2016-01-13 | GlaxoSmithKline Biologicals SA | Compositions à base de combinaisons de Neisseria |
GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
MXPA02006962A (es) | 2000-01-17 | 2002-12-13 | Chiron Spa | Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b. |
JP5511117B2 (ja) | 2000-07-27 | 2014-06-04 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
CU23377A1 (es) * | 2003-11-04 | 2009-05-28 | Ct De Ingenieria Genetica Y Biotecnologia | Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes |
GB0416120D0 (en) | 2004-07-19 | 2004-08-18 | Health Prot Agency | Stable compositions containing OMV's |
US8029777B2 (en) * | 2004-08-13 | 2011-10-04 | Marshall Barry J | Helicobacter system and uses thereof |
CN102078622A (zh) | 2004-08-13 | 2011-06-01 | 巴里.J.马沙尔 | 细菌递送系统 |
GB0419627D0 (en) * | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
CA2590974C (fr) * | 2005-01-27 | 2017-10-03 | Children's Hospital & Research Center At Oakland | Vaccins vesiculaires a base de gna1870 conferant une protection a large spectre contre les maladies provoquees par neisseria meningitidis |
WO2006091517A2 (fr) * | 2005-02-18 | 2006-08-31 | Novartis Vaccines And Diagnostics Inc. | Immunogenes d'escherichia coli uropathogene |
US20090074712A1 (en) * | 2005-05-19 | 2009-03-19 | Compton | Methods for Treatment and Prevention of Infection |
SI1896065T2 (sl) | 2005-06-27 | 2014-12-31 | Glaxosmithkline Biologicals S.A. | Postopek za pripravo cepiv |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
AU2016204760A1 (en) * | 2006-04-26 | 2016-07-28 | Wyeth Llc | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
AU2014268186C1 (en) * | 2006-04-26 | 2017-12-07 | Wyeth Llc | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
US20100285069A1 (en) | 2007-10-19 | 2010-11-11 | Mario Contorni | Meningococcal vaccine formulations |
EP2245048B1 (fr) | 2008-02-21 | 2014-12-31 | Novartis AG | Polypeptides fhbp à méningocoques |
GB0819633D0 (en) * | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
AU2009329193A1 (en) | 2008-12-17 | 2011-07-14 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
BRPI1009828A2 (pt) | 2009-03-24 | 2019-03-12 | Novartis Ag | adjuvante de proteína de ligação de fator h meningocócica |
AU2010242905B2 (en) * | 2009-04-30 | 2014-10-23 | Children's Hospital & Research Center At Oakland | Chimeric factor H binding proteins (fHbp) and methods of use |
EP2440245B1 (fr) | 2009-06-10 | 2017-12-06 | GlaxoSmithKline Biologicals SA | Vaccins contenant benzonaphtyridines |
US20110045564A1 (en) * | 2009-08-20 | 2011-02-24 | Srisuda Dhamwichukorn | Method of enhanced sustainable production of algal bio-products, comprising use of symbiotic diazotroph-attenuated stress co-cultivation |
CN102596240B (zh) | 2009-08-27 | 2015-02-04 | 诺华股份有限公司 | 包括脑膜炎球菌fHBP序列的杂交多肽 |
BR112012004276A2 (pt) | 2009-08-27 | 2017-10-24 | Novartis Ag | adjuvante compreendendo alumínio, oligonucleotídeo e policátion |
KR101430283B1 (ko) | 2009-09-01 | 2014-08-14 | 주식회사이언메딕스 | 장내 공생 세균유래 세포밖 소포체, 및 이를 이용한 질병모델, 백신, 후보 약물 탐색 방법, 및 진단 방법 |
WO2011027956A2 (fr) | 2009-09-04 | 2011-03-10 | 주식회사이언메딕스 | Vésicules extracellulaires issues de bactéries à gram positif, et modèle de maladie utilisant celles-ci |
DK2459216T3 (da) | 2009-09-02 | 2013-12-09 | Novartis Ag | Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer |
TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為tlr活性調節劑之化合物及組合物 |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
WO2011039631A2 (fr) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression de polypeptides fhbp méningococciques |
MX2012004850A (es) | 2009-10-27 | 2012-05-22 | Novartis Ag | Polipeptidos fhbp meningococicos modificados. |
WO2011057148A1 (fr) | 2009-11-05 | 2011-05-12 | Irm Llc | Composés et compositions permettant de moduler l'activité des tlr-7 |
JP5814933B2 (ja) | 2009-12-15 | 2015-11-17 | ノバルティス アーゲー | 免疫増強化合物の均質な懸濁物およびその使用 |
EP2547357A1 (fr) | 2010-03-18 | 2013-01-23 | Novartis AG | Vaccins adjuvantés contre le méningocoque de sérogroupe b |
EA023725B1 (ru) | 2010-03-23 | 2016-07-29 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
US9066971B2 (en) | 2010-07-01 | 2015-06-30 | Postech Academy-Industry Foundation | Method for treating and diagnosing cancer by using cell-derived microvesicles |
HUE052850T2 (hu) | 2010-08-23 | 2021-05-28 | Wyeth Llc | Neisseria meningitidis RLP2086 antigéneket tartalmazó stabil készítmények |
AU2011300418B2 (en) | 2010-09-10 | 2016-05-12 | Glaxosmithkline Biologicals Sa | Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom |
ES2585328T5 (es) | 2010-09-10 | 2022-12-14 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
EP2707009A1 (fr) | 2011-05-12 | 2014-03-19 | Novartis AG | Antipyrétiques pour améliorer la tolérabilité de vaccins à base de vésicules |
DK2729167T3 (en) * | 2011-07-07 | 2018-04-30 | De Staat Der Nederlanden Vert Door De Mini Van Vws | PROCEDURE FOR DETERGENT-FREE PREPARATION OF Outer Membrane Vesicles by a Gram-Negative Bacteria |
CN104114706A (zh) | 2012-02-02 | 2014-10-22 | 诺华股份有限公司 | 用于脑膜炎球菌中增加的蛋白表达的启动子 |
WO2013132040A2 (fr) | 2012-03-08 | 2013-09-12 | Novartis Ag | Dosage de puissance in vitro pour des vaccins méningococciques à base de protéine |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
MY167723A (en) | 2012-03-09 | 2018-09-21 | Pfizer | Neisseria meningitidis compositions and methods thereof |
EP2833911A4 (fr) | 2012-04-06 | 2016-07-13 | Univ Cornell | Plateforme de délivrance de vaccins sous-unité pour réponses immunitaires humorales et cellulaires robustes |
BR112014031386A2 (pt) | 2012-06-14 | 2017-08-01 | Pasteur Institut | vacinas para meningococos do sorogrupo x |
US10000545B2 (en) | 2012-07-27 | 2018-06-19 | Institut National De La Sante Et De La Recherche Medicale | CD147 as receptor for pilus-mediated adhesion of Meningococci to vascular endothelia |
CN104602705A (zh) | 2012-09-06 | 2015-05-06 | 诺华股份有限公司 | 血清组b脑膜炎球菌和d/t/p的联合疫苗 |
EP2897635A1 (fr) | 2012-09-18 | 2015-07-29 | Novartis AG | Vésicules de membrane externe |
CN105163724A (zh) | 2013-02-07 | 2015-12-16 | 葛兰素史密丝克莱恩生物有限公司 | 包含囊泡的药物组合物 |
JP6446377B2 (ja) | 2013-03-08 | 2018-12-26 | ファイザー・インク | 免疫原性融合ポリペプチド |
CA2923129C (fr) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Compositions utilisables contre neisseria meningitidis et procedes associes |
MX2016011176A (es) | 2014-02-28 | 2017-02-23 | Glaxosmithkline Biologicals Sa | Polipeptidos fhbp meningococicos modificados. |
BR112017017460A2 (pt) | 2015-02-19 | 2018-04-10 | Pfizer Inc. | composições de neisseria meningitidis e métodos das mesmas |
EP3298031B1 (fr) | 2015-05-18 | 2020-10-21 | BiOMVis Srl | Compositions immunogènes comprenant des vesicules de membrane externe bacteriennes et leur utilisation |
CA3004924A1 (fr) * | 2015-11-10 | 2017-05-18 | Ohio State Innovation Foundation | Methodes et compositions associees a une affinite humorale acceleree |
WO2018042015A1 (fr) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccins contre neisseria gonorrhoeae |
AU2017347870A1 (en) * | 2016-10-28 | 2019-05-02 | Vedanta Biosciences, Inc. | Methods and compositions for preserving bacteria |
US10183070B2 (en) | 2017-01-31 | 2019-01-22 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
WO2018179003A2 (fr) * | 2017-03-31 | 2018-10-04 | Indian Council Of Medical Research | Vaccin à base de vésicules de membrane externe bivalentes (bomv) contre les salmonelles typhiques |
US10793865B2 (en) | 2018-06-05 | 2020-10-06 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Transferrable mechanism of generating inducible, BAR domain protein-mediated bacterial outer membrane extensions |
EP3607967A1 (fr) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Polypeptides modifiés du méningocoque fhbp |
US20230201325A1 (en) | 2018-11-06 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
WO2020172492A2 (fr) * | 2019-02-22 | 2020-08-27 | Evelo Biosciences, Inc. | Préparations de membrane bactérienne |
US20220378902A1 (en) * | 2019-08-22 | 2022-12-01 | Sichuan University | Bacterial membrane vesicles, and separation and preparation system and method therefor |
CN110563829B (zh) * | 2019-09-17 | 2021-03-26 | 中国人民解放军国防科技大学 | 用于调控脂质体囊泡行为、功能的反光蛋白体系及其应用 |
EP3799884A1 (fr) | 2019-10-01 | 2021-04-07 | GlaxoSmithKline Biologicals S.A. | Compositions immunogènes |
KR20230066041A (ko) | 2020-09-11 | 2023-05-12 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 외막 소포 |
GB202115077D0 (en) | 2021-10-21 | 2021-12-08 | Glaxosmithkline Biologicals Sa | Assay |
WO2023097652A1 (fr) * | 2021-12-03 | 2023-06-08 | National Center For Nanoscience And Technology | Cellule modifiée et son application |
GB202211033D0 (en) | 2022-07-28 | 2022-09-14 | Glaxosmithkline Biologicals Sa | Purification process |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
US4707543A (en) * | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
JPH01125328A (ja) | 1987-07-30 | 1989-05-17 | Centro Natl De Biopreparados | 髄膜炎菌ワクチン |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
AU640118B2 (en) | 1988-12-19 | 1993-08-19 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Meningococcal class 1 outer-membrane protein vaccine |
ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
US5993826A (en) | 1993-03-02 | 1999-11-30 | Board Of Regents, The University Of Texas | Methods and compositions relating to useful antigens of moraxella catarrhalis |
US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
WO1993018150A1 (fr) | 1992-03-02 | 1993-09-16 | Biocine S.P.A. | Proteines d'helicobacter pylori utiles pour des vaccins et des diagnostics |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
FR2692592B1 (fr) * | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
SG49909A1 (en) | 1992-06-25 | 1998-06-15 | Smithkline Beecham Biolog | Vaccine composition containing adjuvants |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
NL9201716A (nl) | 1992-10-02 | 1994-05-02 | Nederlanden Staat | Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat. |
PT624376E (pt) * | 1993-05-13 | 2000-07-31 | American Cyanamid Co | Preparacao e utilizacoes de proteinas de membranas externas deficitarias em los de cocos gram-negativos |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
EP0710118B1 (fr) * | 1994-04-20 | 1998-11-25 | U.S. Department Of The Army | Vaccin contre les infections par des bacteries gram-negatives |
EP0769018B1 (fr) | 1994-07-01 | 2002-12-18 | Chiron Corporation | Proteines d'helicobacter et vaccins |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
PT772619E (pt) | 1994-07-15 | 2006-10-31 | Univ Iowa Res Found | Oligonucleotidos imunomoduladores |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
EP0841944A2 (fr) | 1995-08-04 | 1998-05-20 | University Of Guelph | Nouveaux vaccins et nouvelles compositions pharmaceutiques utilisant des vesicules de membrane de micro-organismes et leurs procedes d'elaboration |
EP0909323B1 (fr) | 1996-01-04 | 2007-02-28 | Novartis Vaccines and Diagnostics, Inc. | Bacterioferritine de helicobacter pilori |
DE19630390A1 (de) | 1996-07-26 | 1998-01-29 | Chiron Behring Gmbh & Co | Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung |
CA2268825C (fr) | 1996-10-11 | 2006-04-18 | The Regents Of The University Of California | Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice |
NZ337054A (en) | 1997-01-30 | 2001-03-30 | Chiron Corp | Microparticles PLA and PLG with adsorbed viral antigen to stimulate immune responses particularly for intracellular viruses such as HSV-1 or HSV-2, varicella zoster virus. epstein-barr virus or cytomegalovirus (CMV) |
JP2001513776A (ja) | 1997-02-28 | 2001-09-04 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | LPS関連障害の処置における非メチル化CpGジヌクレオチドを含む核酸の使用 |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
AU7690898A (en) | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
JP4101888B2 (ja) | 1997-06-06 | 2008-06-18 | ダイナバックス テクノロジーズ コーポレイション | 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法 |
GB9711964D0 (en) | 1997-06-09 | 1997-08-06 | Medical Res Council | Live attenuated vaccines |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
CA2297072A1 (fr) * | 1997-07-17 | 1999-01-28 | North American Vaccine, Inc. | Conjugues immunogenes renfermant une porine meningococcique du groupe b et un polysaccharide h. influenzae |
CA2300854C (fr) | 1997-08-21 | 2011-04-05 | Peter Andre Van Der Ley | Nouveaux mutants de bacteries des muqueuses gram negatives et leur application dans des vaccins |
EP1279401B1 (fr) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Emulsions du type huile-dans-l'eau contenant des saponines |
DE69841807D1 (de) | 1997-11-06 | 2010-09-16 | Novartis Vaccines & Diagnostic | Neisseriale antigene |
WO1999027105A2 (fr) | 1997-11-21 | 1999-06-03 | Genset | Sequence genomique et polypeptides de chlamydia pneumoniae, leurs fragments et leurs utilisations, en particulier pour le diagnostic, la prevention ou le traitement d'une infection |
CN1280619A (zh) | 1997-11-28 | 2001-01-17 | 根瑟特公司 | 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染 |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
DK1047784T4 (en) | 1998-01-14 | 2015-06-15 | Novartis Vaccines & Diagnostic | NEISSERA meningitidis ANTIGENS |
GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
AU746163B2 (en) | 1998-04-09 | 2002-04-18 | Smithkline Beecham Biologicals (Sa) | Adjuvant compositions |
EP2261351A3 (fr) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Antigènes de Neisseria meningitidis et compositions |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
AU1202200A (en) * | 1998-10-09 | 2000-05-01 | Chiron Corporation | Neisseria genomic sequences and methods of their use |
TR200101055T2 (tr) | 1998-10-16 | 2001-09-21 | Smithkline Beecham Biologicals S.A. | Adjuvan sistemler ve aşılar |
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
CA2350775A1 (fr) | 1998-11-12 | 2000-05-18 | The Regents Of The University Of California | Sequence genomique de chlamydia pneumoniae |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
WO2000045841A2 (fr) * | 1999-02-05 | 2000-08-10 | Merck & Co., Inc. | Formulations vaccinales contre le virus du papillome humain |
US7081244B2 (en) * | 1999-02-22 | 2006-07-25 | Health Protection Agency | Neisserial vaccine compositions and methods |
WO2000050074A2 (fr) | 1999-02-22 | 2000-08-31 | Microbiological Research Authority | Compositions de vaccin a neisseria et procedes correspondants |
ES2350306T3 (es) | 1999-02-26 | 2011-01-20 | Novartis Vaccines And Diagnostics, Inc. | Uso de bioadhesivos y adyuvantes para la administración de antígenos por vía mucosa. |
SI1162999T1 (sl) | 1999-03-19 | 2007-04-30 | Glaxosmithkline Biolog Sa | Vakcina proti Streptococcus pneumoniae |
US6245568B1 (en) * | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア |
ES2228497T3 (es) | 1999-04-19 | 2005-04-16 | Glaxosmithkline Biologicals S.A. | Composicion adyuvante que comprende saponina y un oligonucleotido inmunoestimulante. |
AUPQ005499A0 (en) * | 1999-04-30 | 1999-05-27 | Townsend, Roy Leslie | Printing process |
ES2477194T3 (es) | 1999-04-30 | 2014-07-16 | Novartis Vaccines And Diagnostics S.R.L. | Ant�genos neisseriales conservados |
EP2270172B1 (fr) | 1999-05-19 | 2016-01-13 | GlaxoSmithKline Biologicals SA | Compositions à base de combinaisons de Neisseria |
GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
AR025749A1 (es) | 1999-09-24 | 2002-12-11 | Smithkline Beecham Biolog | Vacunas |
MXPA02003067A (es) | 1999-09-24 | 2002-09-30 | Smithkline Beecham Biolog | Uso de combinacion de ester sorbitano de polioxietileno y octoxinol como adjuvante y su uso en vacunas. |
WO2001034642A2 (fr) | 1999-11-12 | 2001-05-17 | University Of Iowa Research Foundation | Commande de la synthese de membrane de neisseria |
MXPA02006962A (es) | 2000-01-17 | 2002-12-13 | Chiron Spa | Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b. |
GB0007433D0 (en) * | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Recombinant transferrin binding proteins |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
ATE440861T1 (de) | 2000-07-03 | 2009-09-15 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
GB0017149D0 (en) | 2000-07-12 | 2000-08-30 | Chiron Spa | Helicobacter pylori mutants |
JP5511117B2 (ja) * | 2000-07-27 | 2014-06-04 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
CA2420621C (fr) | 2000-09-28 | 2011-05-24 | Chiron Corporation | Compositions de microparticules et procede de fabrication desdites compositions |
AU2002214127B2 (en) | 2000-10-27 | 2007-06-07 | J. Craig Venter Institute, Inc. | Nucleic acids and proteins from streptococcus groups A and B |
GB0103171D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
WO2003009869A1 (fr) | 2001-07-26 | 2003-02-06 | Chiron Srl. | Vaccins comprenant des adjuvants aluminium et histidine |
GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
GB0130123D0 (en) * | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
ES2537737T3 (es) * | 2002-08-02 | 2015-06-11 | Glaxosmithkline Biologicals S.A. | Composiciones de vacuna que comprenden lipooligosacáridos de inmunotipo L2 y/o L3 de Neisseria meningitidis de IgtB |
-
2002
- 2002-08-30 GB GBGB0220194.5A patent/GB0220194D0/en not_active Ceased
-
2003
- 2003-09-01 DK DK07012893.9T patent/DK1864679T3/da active
- 2003-09-01 PT PT03791150T patent/PT1534326E/pt unknown
- 2003-09-01 NZ NZ538673A patent/NZ538673A/en not_active IP Right Cessation
- 2003-09-01 ES ES03791150T patent/ES2289351T3/es not_active Expired - Lifetime
- 2003-09-01 PT PT101797835T patent/PT2258389E/pt unknown
- 2003-09-01 PT PT70128939T patent/PT1864679E/pt unknown
- 2003-09-01 CN CNA038237237A patent/CN1688334A/zh active Pending
- 2003-09-01 ES ES10179783T patent/ES2423019T3/es not_active Expired - Lifetime
- 2003-09-01 MX MXPA05002316A patent/MXPA05002316A/es active IP Right Grant
- 2003-09-01 AT AT03791150T patent/ATE366117T1/de active
- 2003-09-01 EP EP10179782.7A patent/EP2258388B1/fr not_active Expired - Lifetime
- 2003-09-01 RU RU2005108994/15A patent/RU2325184C2/ru not_active IP Right Cessation
- 2003-09-01 DK DK03791150T patent/DK1534326T3/da active
- 2003-09-01 SI SI200332378T patent/SI1864679T1/sl unknown
- 2003-09-01 SI SI200332269T patent/SI2258389T1/sl unknown
- 2003-09-01 EP EP10179783.5A patent/EP2258389B1/fr not_active Expired - Lifetime
- 2003-09-01 US US10/526,113 patent/US20060166344A1/en not_active Abandoned
- 2003-09-01 AU AU2003263534A patent/AU2003263534B2/en not_active Ceased
- 2003-09-01 EP EP03791150A patent/EP1534326B1/fr not_active Revoked
- 2003-09-01 CA CA2497165A patent/CA2497165C/fr not_active Expired - Fee Related
- 2003-09-01 WO PCT/IB2003/004293 patent/WO2004019977A2/fr active IP Right Grant
- 2003-09-01 EP EP10179787A patent/EP2258390A1/fr not_active Withdrawn
- 2003-09-01 ES ES07012893.9T patent/ES2483592T3/es not_active Expired - Lifetime
- 2003-09-01 ES ES10179782.7T patent/ES2520392T3/es not_active Expired - Lifetime
- 2003-09-01 BR BRPI0314094A patent/BRPI0314094A8/pt not_active IP Right Cessation
- 2003-09-01 CN CN2011101128386A patent/CN102188700A/zh active Pending
- 2003-09-01 EP EP07012893.9A patent/EP1864679B1/fr not_active Expired - Lifetime
- 2003-09-01 JP JP2004532626A patent/JP2006503822A/ja not_active Withdrawn
- 2003-09-01 DE DE60314756T patent/DE60314756T2/de not_active Expired - Lifetime
- 2003-09-01 DK DK10179783.5T patent/DK2258389T3/da active
-
2007
- 2007-09-17 CY CY20071101197T patent/CY1107737T1/el unknown
-
2010
- 2010-03-23 JP JP2010067009A patent/JP2010150287A/ja not_active Withdrawn
-
2013
- 2013-03-29 JP JP2013072014A patent/JP5808358B2/ja not_active Expired - Fee Related
- 2013-07-04 LU LU92239C patent/LU92239I2/fr unknown
- 2013-07-31 FR FR13C0046C patent/FR13C0046I2/fr active Active
- 2013-09-02 CY CY20131100752T patent/CY1114570T1/el unknown
-
2014
- 2014-09-11 CY CY20141100736T patent/CY1115777T1/el unknown
-
2015
- 2015-06-01 US US14/727,248 patent/US20150258188A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR13C0046I2 (fr) | Vesicules de membrane externe bacterienne ameliorees | |
JP2006503822A5 (fr) | ||
NO963508L (no) | Urease-basert vaksine og behandling av Helicobacter-infeksjon | |
AU2003244855A1 (en) | Method to enhance an immune response of nucleic acid vaccination | |
DE69831594D1 (de) | Intakte oder zerstörte insektenzellen als antigenadjuvant | |
AU1463097A (en) | Helicobacter pylori bacterioferritin | |
WO2003105784A8 (fr) | Compositions et procedes pour adoucir, fluidifier et enlever le tissu hyperkeratosique | |
WO2005112994A8 (fr) | Composition d'immunisation comportant des vlp de type nodavirus | |
EP1583502A4 (fr) | Procedes et reactifs pour l'amelioration de la transduction virale dans l'epithelium de la vessie | |
DE60041157D1 (de) | Verfahren zur verbesserung der gentransfer-effizienz in pflanzenzellen | |
CA2514332A1 (fr) | Procede d'inactivation/elimination d'agents pathogenes presents sur un tissu | |
ATE404547T1 (de) | Verfahren zur herstellung von propylenoxid | |
EP1546357A4 (fr) | Polypeptides immunogenes de mycoplasma hyopneumoniae | |
RU2008148606A (ru) | Способ экстракции компонентов из культуры дрожжевых клеток | |
ES2074968B1 (es) | Nuevas cepas de pseudomonas aeruginosa atenuadas. | |
RU2008111708A (ru) | Способ получения эмбриональных фибробластоподобных клеток из пупочного канатика новорожденного | |
CN114395525A (zh) | 一种脱细胞去抗原的异种肌腱制备方法 | |
IT1317849B1 (it) | Mezzi e metodi per l'espressione di proteine omologhe ed eterologhe inceppi di rhodococcus. | |
AR029547A1 (es) | Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon | |
GB0407828D0 (en) | Therapeutic composition for autoimmune conditions | |
RU2002132049A (ru) | Способ получения липополисахаридов | |
WO2006020824A3 (fr) | Diagnostic et traitement de la maladie de kawasaki et d'une infection a coronavirus | |
BR0311463A (pt) | Composições compreendendo uma bactéria do gênero dietzia que são úteis para o tratamento de paratuberculose em ruminantes e método para a cultura da bactéria | |
ATE496745T1 (de) | Holzbehandlungsmethode | |
RU2003134680A (ru) | Способ получения эндонуклеазы рестрикции spm i |